Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 727

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 5
Chunk 727
---
Market
Information

Our
common stock is listed on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and ticker symbol “INDP”.

Holders

As
of March 12, 2025, we had 22 record holders of our common stock. This number does not include the number of persons whose shares are
in nominee or in “street name” accounts through brokers.

Dividend
Policy

We
have never declared or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future.
We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy
will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable
law and other factors that our board of directors may deem relevant.

Securities
Authorized for Issuance under Equity Compensation Plans

Information
about our equity compensation plan under which the Company’s equity securities are authorized for issuance is set forth in “Part
III - Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of this Annual Report.

Recent
Sales of Unregistered Securities

None.

Purchases
of Equity Securities by the Issuer and Affiliated Purchasers

We
did not repurchase any of our equity securities during the quarter ended December 31, 2024.

Item
6. [Reserved]

63

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You
should read the following discussion and analysis of our financial condition and results of operations along with our consolidated financial
statements and the related notes and other financial information included elsewhere in this Annual Report. The following discussion contains
forward-looking statements that are subject to risks, uncertainties and assumptions. You should review the sections titled “Summary
Risk Factors” and Part I, Item 1A. “Risk Factors” in this Annual Report for a discussion of important factors that
could cause actual results to differ materially from the results described below.

Overview

We
are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti